Welcome to our dedicated page for Tharimmune SEC filings (Ticker: THAR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tharimmune, Inc. (NASDAQ: THAR) SEC filings page on Stock Titan aggregates the company’s official disclosures filed with the U.S. Securities and Exchange Commission, including its Current Reports on Form 8-K, proxy materials, and other registration documents. These filings provide primary-source detail on Tharimmune’s clinical-stage biotechnology programs and its Canton Coin-focused digital asset treasury strategy.
Recent Form 8-K filings describe material definitive agreements such as securities purchase agreements for private placements involving common stock and pre-funded warrants, as well as an at-the-market sales agreement for common stock. They also outline the structure and intended use of proceeds from offerings designed to support both Tharimmune’s historical biotech operations and the establishment of a Canton Coin treasury and related Canton Network participation.
Other 8-Ks and proxy materials detail corporate governance and compensation matters, including amendments to the certificate of incorporation to increase authorized common stock, changes to the omnibus equity incentive plan, and the appointment of key executives such as the Chief Executive Officer, President, and Chief Financial Officer. These documents specify employment agreement terms, severance provisions, and equity award structures for senior leadership associated with the company’s biotechnology and digital asset initiatives.
Investors can also use this page to access risk factor discussions related to Tharimmune’s Canton Coin strategy, as described in its filings, including risks tied to digital asset volatility, regulatory uncertainty, and liquidity considerations. Proxy statements provide additional context on share authorization proposals and future offering authorizations under Nasdaq rules.
Stock Titan enhances these filings with AI-powered summaries that highlight key terms, capital structure changes, and leadership updates, helping readers quickly interpret complex legal and financial language. From here, you can review Tharimmune’s 8-Ks, registration statements, and proxy materials, and use the platform’s tools to track insider-related disclosures and ongoing financing arrangements as they appear in the EDGAR feed.
Tharimmune, Inc. reported that its Compensation Committee approved higher pay and severance protections for its top two executives. The base salary for CEO Sireesh Appajosyula and Executive Chairman Vincent LoPriore was each increased by
The Committee also enhanced their change-of-control benefits. If either executive is terminated within twelve months after a change of control, their severance will rise from two times to three times base salary and target bonus, strengthening their contractual protections in a potential sale or merger scenario.
Tharimmune, Inc. reported that it has regained compliance with Nasdaq listing requirements related to stockholders’ equity. On September 5, 2025, the company received a letter from Nasdaq confirming that, based on a filing showing stockholders’ equity of $6,876,335 as of August 31, 2025, it meets Nasdaq Listing Rule 5550(b)(1). Nasdaq stated that the compliance matter is now closed, meaning Tharimmune’s common stock continues to qualify for listing on The Nasdaq Stock Market.
Tharimmune, Inc. filed Amendment No. 1 to its Form S-3 registration statement, focused on updating back-end disclosure items rather than changing the preliminary prospectus. The amendment revises Item 16 and adds or updates certain exhibits, including legal opinions, consents and previously filed corporate and transaction documents. It also details estimated offering-related expenses, with total fees and costs of $90,819.88, including SEC registration, legal, accounting, printing and miscellaneous expenses, which are to be borne by the selling stockholders (other than underwriting discounts and commissions). The filing restates the company’s indemnification provisions for directors and officers under Delaware law and confirms standard Securities Act undertakings and signature authorizations.
Nancy Davis Rickel, a director of Tharimmune, Inc. (THAR), filed an initial Form 3 disclosing ownership of 50,000 stock options granted on 08/04/2025. The options are exercisable into common stock at an exercise price of $1.33 per share, with 25,000 shares vesting immediately and 25,000 vesting on 08/04/2026. The filing is signed by Ms. Rickel on 08/29/2025 and was filed as an individual Form 3.
Tharimmune, Inc. is offering securities that raise approximately $4,814,996 in gross proceeds, with placement agent fees of $535,000 (10% of gross proceeds). The prospectus supplement shows common stock outstanding rising from 5,691,444 shares before the offering to 6,880,332 shares after the offering, and a pro forma net tangible book value per share of $0.09 as of June 30, 2025. Net proceeds are intended for working capital and general corporate purposes. The company states it has never paid cash dividends and does not anticipate doing so. Tharimmune’s Quatramer platform is described as a proprietary tumor-targeting approach to deliver drugs to the tumor microenvironment. The filing also discloses dependence on sole-source suppliers for certain ingredients and highlights that investing involves a high degree of risk.
Tharimmune, Inc. is registering 2,463,601 shares of common stock for resale by existing investors from recent July 2025 financings. The registered shares include 974,241 shares issuable upon exercise of common warrants from a July 28, 2025 registered direct offering and 1,489,360 shares from a July 31, 2025 private placement, made up of common shares, pre-funded warrant shares and additional common warrant shares. Tharimmune is not selling any stock in this prospectus and will not receive proceeds from these resales, but may receive cash if investors exercise the registered warrants, which it expects to use for product development and working capital.
The company is a clinical-stage biotechnology business focused on immunology and inflammation. Lead candidate TH104 targets severe pruritus and a new indication for prophylaxis against high-potency opioids, where the FDA has given positive feedback on a 505(b)(2) NDA path that may not require additional clinical trials for that use. Tharimmune also licenses an oral infliximab program (TH023) and maintains an early immuno-oncology pipeline. As of August 22, 2025, 5,336,441 common shares were outstanding, and the company faces Nasdaq listing risk after reporting stockholders’ equity of $1,307,642, below the $2,500,000 requirement.
Tharimmune, Inc. entered into a securities purchase agreement for a registered direct offering of $5.35 million of its securities. The deal covers 1,188,888 shares of common stock (or common stock equivalents) at a price of $4.50 per share, using an existing shelf registration statement on Form S-3.
The company appointed President Street Global, LLC and RF Lafferty & Co., Inc. as exclusive co-placement agents and agreed to pay them a 10.0% cash fee on the aggregate gross proceeds. The offering, which includes shares underlying pre-funded warrants, is expected to close on August 27, 2025 subject to customary conditions.
Tharimmune, Inc. entered into a securities purchase agreement for a registered direct offering of its common stock. The company agreed to sell 1,188,888 shares of common stock (or common stock equivalents) at $4.50 per share, for total securities of $5.35 million, under an effective shelf registration statement on Form S-3.
The shares are being offered through a prospectus supplement and base prospectus filed with the SEC, and the offering is expected to close on August 27, 2025, subject to customary closing conditions. Tharimmune engaged President Street Global, LLC and RF Lafferty & Co., Inc. as exclusive co-placement agents and agreed to pay them a 10.0% cash fee on the aggregate gross proceeds from the sale.
Tharimmune director Thomas Clay Kahler filed an initial Form 3 reporting ownership of a derivative security: a stock option to buy 50,000 shares of Tharimmune common stock (ticker THAR) with an exercise price of $1.33. The option has an expiration date of 08/04/2035; 25,000 shares vested on grant and 25,000 vest on 08/04/2026. The Form 3 indicates the filing was made by one reporting person.
James Gordon Liddy filed an Initial Statement on Form 3 reporting his beneficial ownership in Tharimmune, Inc. (THAR). The filing, tied to an event dated 06/11/2025, shows a stock option granting the right to purchase 50,000 shares of common stock at an exercise price of $1.33 per share. The reporting person is identified as a Director. The explanatory note states that 25,000 options vested on the date of grant and the remaining 25,000 vest on 08/04/2026. The form is signed by the reporting person on 08/22/2025. The ownership is reported as direct.